Effects induced by sodium-glucose cotransporter inhibitors (SGLTi) in subjects with cardiovascular disease

JP2026503669APending Publication Date: 2026-01-29F HOFFMANN LA ROCHE & CO AG
1 Cites -1 Cited by

Patent Information

Application Number
JP2025543261
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-01-30
Filing Date
2024-01-30
Publication Date
2026-01-29

Smart Images

  • Figure 2026503669000001_ABST
    Figure 2026503669000001_ABST
Patent Text Reader

Abstract

The present invention relates to a method for detecting the effects induced by sodium-glucose cotransporter inhibitors (SGLTi) in subjects suffering from cardiovascular disease, comprising: a) determining the amount of fatty acid binding protein 3 (FABP3) in a sample of a subject treated with SGLTi; and b) comparing the amount of FABP3 with a reference amount.Computer-implemented methods, computer program products, devices, and kits for carrying out the methods of the present invention are also included.The present invention further relates to the use of FABP3, the use of FABP3 and cardiac injury markers, and / or the use of a detection agent for FABP3, or FABP3 and cardiac injury markers, for detecting the effects induced by sodium-glucose cotransporter inhibitors (SGLTi) in subjects suffering from cardiovascular disease.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • NTproBNP AND cTnT BASED THERAPY GUIDANCE IN HEART FAILURE

    US20180313850A1